- Home
- RL vs RPRX Comparison
RL vs RPRX Comparison
Compare RL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RL
- RPRX
- Stock Information
- Founded
- RL 1967
- RPRX 1996
- Country
- RL United States
- RPRX United States
- Employees
- RL N/A
- RPRX N/A
- Industry
- RL Apparel
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RL Consumer Discretionary
- RPRX Health Care
- Exchange
- RL Nasdaq
- RPRX Nasdaq
- Market Cap
- RL 13.1B
- RPRX 14.3B
- IPO Year
- RL 1997
- RPRX 2020
- Fundamental
- Price
- RL $276.66
- RPRX $32.88
- Analyst Decision
- RL Strong Buy
- RPRX Strong Buy
- Analyst Count
- RL 15
- RPRX 4
- Target Price
- RL $304.64
- RPRX $42.50
- AVG Volume (30 Days)
- RL 835.2K
- RPRX 5.8M
- Earning Date
- RL 05-22-2025
- RPRX 05-08-2025
- Dividend Yield
- RL 1.32%
- RPRX 2.68%
- EPS Growth
- RL 19.57
- RPRX 37.60
- EPS
- RL 11.61
- RPRX 2.45
- Revenue
- RL $7,079,000,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- RL $6.44
- RPRX $31.16
- Revenue Next Year
- RL $4.37
- RPRX $6.37
- P/E Ratio
- RL $23.84
- RPRX $13.41
- Revenue Growth
- RL 6.75
- RPRX 1.13
- 52 Week Low
- RL $155.96
- RPRX $24.05
- 52 Week High
- RL $289.33
- RPRX $34.32
- Technical
- Relative Strength Index (RSI)
- RL 64.55
- RPRX 51.49
- Support Level
- RL $263.18
- RPRX $32.15
- Resistance Level
- RL $286.77
- RPRX $32.82
- Average True Range (ATR)
- RL 7.95
- RPRX 0.72
- MACD
- RL -0.21
- RPRX -0.07
- Stochastic Oscillator
- RL 62.45
- RPRX 33.72
About RL Ralph Lauren Corporation
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.